CDK INHIBITORS Flashcards
palbociclib
1
Q
G0 exit controller
A
C-CDK 3
2
Q
G1/S transition controller
A
cyclin D - CDK 4/6
THAN
CYCLIN E- CDK 2 complex
3
Q
G2/M Transition
A
Cyclin A / CDK 1/2
+
cyclin B+ cdk 1
4
Q
CDK Inhibitors
A
abemaciclib
palbociclib
ribociclib
5
Q
dosage of cdk
A
palbo 125 mg daily
ribociclib 600 mg daily
abemaciclib 200mg daily
6
Q
indication of palbociclib
A
ER positive breast cancer
mantle cell lymphoma
liposarcoma trial
lung cancer trial
7
Q
which tumors are more sensitive to cdk inhibitors
A
cells with d cyclin active features
